Home/Pipeline/ANAVEX®1-41

ANAVEX®1-41

CNS Disorders

PreclinicalPreclinical

Key Facts

Indication

CNS Disorders

Phase

Preclinical

Status

Preclinical

Company

Anavex Life Sciences

About Anavex Life Sciences

Anavex Life Sciences is a clinical-stage biotech focused on developing oral therapeutics for central nervous system (CNS) disorders by targeting the sigma-1 receptor (SIGMAR1). Its lead asset, blarcamesine, has generated pivotal clinical data in Alzheimer's disease and holds Orphan Drug Designation for Rett syndrome, positioning it in multi-billion dollar markets with high unmet need. The company operates with a lean, virtual model, advancing a precision medicine platform that aims to modify disease pathology rather than just alleviate symptoms.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Neurodevelopmental Disorders

Other CNS Disorders Drugs

Drug	Company	Phase	Status
NanoBUP™	Nanopharmaceutics	Clinical	Active
PRX-3140	Nanopharmaceutics	Clinical	Active
NP-18-2	Nanopharmaceutics	Clinical	Active
NP-18-3	Nanopharmaceutics	Clinical	Active
LPH-48	Lophora	Pre-clinical	Active
Research Collaboration with OliX Pharmaceuticals	Vect-Horus	Research	Active
New Discovery Programs	CAMP4 Therapeutics	Discovery	Active discovery
Next-Gen α7 NAM Program	Neuphoria Therapeutics	Discovery/Preclinical	Active